Ceftazidim Mip Pharma

Leaflet attached to the packaging: patient information

Ceftazidim MIP Pharma, 1 g, powder for solution for injection/infusion

Ceftazidim MIP Pharma, 2 g, powder for solution for injection/infusion

Ceftazidime (Ceftazidimum)

Read the leaflet carefully before using the medicine, as it contains important information for the patient.

• Keep this leaflet, so you can read it again if you need to.
• If you have any doubts, consult your doctor, pharmacist, or nurse.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same as yours.
• If the patient experiences any side effects, including any not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is Ceftazidim MIP Pharma and what is it used for
• 2. Important information before using Ceftazidim MIP Pharma
• 3. How to use Ceftazidim MIP Pharma
• 4. Possible side effects
• 5. How to store Ceftazidim MIP Pharma
• 6. Contents of the packaging and other information

1. What is Ceftazidim MIP Pharma and what is it used for

Ceftazidim MIP Pharma is an antibiotic used in adults and children (including newborns).
It works bactericidally on bacteria that cause infections. It belongs to a group of medicines called
cephalosporins .

Ceftazidim MIP Pharma is used to treat severe bacterial infections:

• lower respiratory tract, including lungs
• lungs and bronchi in patients with cystic fibrosis
• brain (meningitis)
• ear
• urinary tract
• skin and soft tissues
• abdominal cavity and abdominal walls (peritonitis)
• bones and joints.

Ceftazidim MIP Pharma can also be used:

• to prevent infections during transurethral resection of the prostate in men
• to treat patients with a low white blood cell count (neutropenia) who have a fever due to a bacterial infection.

2. Important information before using Ceftazidim MIP Pharma

When not to give Ceftazidim MIP Pharma to the patient

• -If the patient is allergic(hypersensitive) to ceftazidimeor any of the other ingredients of this medicine (listed in section 6).
• -If the patient has ever had a severe allergic reactionto any other antibiotic(penicillins, monobactams, and carbapenems) ,as the patient may also be allergic to Ceftazidim MIP Pharma.
• If the patient suspects that they are affected by the above circumstances, they should tell their doctor beforestarting treatment with Ceftazidim MIP Pharma. Do not give Ceftazidim MIP Pharma to the patient.

When to exercise special caution when using Ceftazidim MIP Pharma

Pay attention to whether the patient experiences any special symptoms during treatment with Ceftazidim MIP Pharma, such as allergic reactions, nervous system disorders, and stomach and intestinal disorders, including diarrhea. This will reduce the risk of possible problems. See ('Adverse reactions to watch out for') in section 4. If the patient has ever had an allergic reaction to other antibiotics, they may also be allergic to Ceftazidim MIP Pharma.
Severe skin reactions have been reported with ceftazidime, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If the patient experiences any of the symptoms associated with these severe skin reactions, described in section 4, they should see a doctor immediately.

Blood and urine tests

Ceftazidim MIP Pharma may change the results of urine sugar tests and blood tests known as the Coombs test. If the patient is to have these tests:

• Tell the person taking the samplethat the patient has taken Ceftazidim MIP Pharma.

Ceftazidim MIP Pharma and other medicines

Tell the doctor or pharmacist about all medicines the patient is taking, has recently taken, or plans to take, including those available without a prescription.
The patient should not take Ceftazidim MIP Pharma without consulting their doctor if they are also taking:

• an antibiotic called chloramphenicol .
• an antibiotic from the group called aminoglycosides, such as gentamicin, tobramycin
• diuretic tablets containing furosemide
• If the above circumstances apply to the patient, tell their doctor.

Pregnancy, breastfeeding, and fertility

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before using this medicine.
The doctor will assess whether the benefits of taking Ceftazidim MIP Pharma during pregnancy and breastfeeding outweigh the risks to the child.

Driving and using machines

Ceftazidim MIP Pharma may cause side effects that affect the ability to drive or operate machinery, such as dizziness.
The patient should not drive or operate machinery unless they are sure that they have not experienced these side effects.

Ceftazidim MIP Pharma contains sodium

Ceftazidim MIP Pharma, 1 g, contains approximately 52 mg of sodium (the main component of common salt) per vial. This corresponds to 2.6% of the maximum recommended daily sodium intake in the diet for adults.
Ceftazidim MIP Pharma, 2 g, contains approximately 104 mg of sodium (the main component of common salt) per vial. This corresponds to 5.2% of the maximum recommended daily sodium intake in the diet for adults.
This should be taken into account for patients controlling their sodium intake.

How to use Ceftazidim MIP Pharma

Ceftazidim MIP Pharma is usually given by a doctor or nurse.It can be given as an intravenous infusionor as an injection directly into a vein or intramuscularly.
Ceftazidim MIP Pharma is prepared by a doctor, pharmacist, or nurse using water for injections or another suitable infusion fluid.

Usual dose

The doctor will decide on the appropriate dose of Ceftazidim MIP Pharma for the patient, taking into account the severity and type of infection, whether the patient is taking any other antibiotics, their body weight, age, and kidney function.

Newborns and infants (0-2 months old)

For every 1 kg of the infant's body weight, 25 to 60 mg of ceftazidime is given per day in two divided doses.
Infants (over 2 months old) and childrenwith a body weight of less than 40 kg For every 1 kg of the infant's or child's body weight, 100 to 150 mg of ceftazidime is given per day in three divided doses. Maximum 6 g per day.
Adults and adolescentswith a body weight of 40 kg or more
1 to 2 g of ceftazidime three times a day. Maximum 9 g per day.

Patients over 65 years old

The daily dose should not be higher than 3 g per day, especially in patients over 80 years old.

Patients with kidney disease

The patient may receive a different dose than usual. The doctor or nurse will decide what dose of Ceftazidim MIP Pharma to give the patient, depending on the severity of the kidney disease. The doctor will closely monitor the patient and may order more frequent kidney function tests.

Using a higher dose of Ceftazidim MIP Pharma than recommended

If a higher dose of Ceftazidim MIP Pharma is used than prescribed: contact the doctor immediately or go to the nearest hospital.

Missing a dose of Ceftazidim MIP Pharma

If the patient misses an injection, it should be given as soon as possible. However, if it is close to the time for the next dose, skip the missed dose. Do not take a double dose (two injections at the same time) to make up for the missed dose.

Stopping Ceftazidim MIP Pharma

Do not stop taking Ceftazidim MIP Pharma without the doctor's advice. In case of any further doubts about using this medicine, consult a doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If the patient experiences any of the following symptoms, they should see a doctor immediately:

• -Red spots on the torso, spots resembling a target or circle, often with central blisters, peeling skin, ulcers in the mouth, throat, nose, genitals, and eyes. These severe skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
• Widespread rash, high body temperature, and swollen lymph nodes (DRESS or drug hypersensitivity syndrome).
• Red, peeling, widespread rash with nodules under the skin and blisters, and simultaneous fever. Symptoms usually occur at the beginning of treatment (acute generalized exanthematous pustulosis).
• -Severe allergic reaction. Symptoms are: swollen, itchy rash, sometimes facial or lip swelling, which can cause difficulty breathing.
• -Nervous system disorders: tremors, seizures, and sometimes coma. These disorders occurred in patients who received too high doses, especially those with kidney disease.

Common side effects

May occur in more than 1 in 10patients:

• diarrhea
• swelling and redness along the vein
• red, itchy rash on the skin
• pain, burning, swelling, or inflammation at the injection site.
• If any of the above symptoms concern the patient, they should tell their doctor.

Common side effects that may appear in blood test results:

• increased number of one type of white blood cell (eosinophilia)
• increased number of platelets involved in blood clotting
• increased activity of liver enzymes.

Uncommon side effects

May occur in more than 1 in 100patients:

• inflammation of the intestines, which can cause pain or diarrhea that may contain blood
• thrush - fungal infections of the mouth or vagina
• headache
• dizziness
• abdominal pain
• nausea or vomiting
• fever and chills.
• Tell the doctorif the patient experiences any of the above symptoms.

Uncommon side effects that may appear in blood test results:

• decreased number of white blood cells
• decreased number of platelets (cells involved in blood clotting)
• increased concentration of urea, urea nitrogen, or creatinine in blood serum.

Rare side effects

May occur in more than 1 in 10,000patients:

• inflammation or kidney failure

Other side effects

Other side effects that have occurred in a small number of patients, but the exact frequency is unknown:

• tingling
• unpleasant taste in the mouth
• yellowing of the whites of the eyes and skin.

Other side effects that may appear in blood test results:

• red blood cells break down too quickly
• increased number of one type of white blood cell in the blood
• significant decrease in the number of white blood cells.

Reporting side effects

If side effects occur, including any not listed in the leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, PL-02 222 Warsaw, tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting side effects can help gather more information on the safety of the medicine.

5. How to store Ceftazidim MIP Pharma

Keep the medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the label and carton after: "EXP". The expiry date refers to the last day of the month.
Do not store above 30°C. Store the vial in the outer packaging to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the packaging and other information

What Ceftazidim MIP Pharma contains

• The active substance is ceftazidime. Each vial contains 1 g or 2 g of ceftazidime (as ceftazidime pentahydrate).
• The other ingredient is sodium carbonate, anhydrous.

What Ceftazidim MIP Pharma looks like and what the pack contains

White or light yellow powder
Ceftazidim MIP Pharma, 1 g, is available in 15 ml glass vials, sealed with a rubber stopper and a flip-off cap.
Ceftazidim MIP Pharma, 2 g, is available in 50 ml glass vials, sealed with a rubber stopper and a flip-off cap.
Pack sizes: cardboard boxes containing 1, 5, or 10 vials.
Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer/importer

MIP Pharma GmbH
Kirkeler Str. 41
66440 Blieskastel, Germany
tel.: 0049 (0) 6842 9609 0
fax: 0049 (0) 6842 9609 355

Date of last revision of the leaflet: 12.12.2024

-----------------------------------------------------------------------------------------------------------------------------
Information intended only for healthcare professionals:
When dissolving the powder, the pressure increases due to the release of carbon dioxide. Small carbon dioxide bubbles in the prepared solution can be ignored.

Instructions for preparing the medicine for use

Refer to the table of added volumes and achieved concentrations, which may be useful when partial doses are needed.

The color of the solution ranges from light yellow to amber, depending on the concentration, type of solvent, and storage conditions. If the recommended conditions are met, the variability of the solution's color does not adversely affect the product's effectiveness.
Compatibility with intravenous fluids
The following solvents can be used to prepare the solution:

• water for injections,
• glucose solution 50 mg/ml (5%),
• sodium chloride solution 9 mg/ml (0.9%).

Ceftazidime for intramuscular injections can be dissolved in a solution containing 1% lidocaine hydrochloride for injection.
Preparing the solution for rapid injection

• 1. Pierce the stopper with a needle and inject the recommended volume of solvent into the vial. Withdraw the needle with the syringe.
• 2. Shake until dissolved: carbon dioxide is released and a clear solution is obtained within 1 to 2 minutes.
• 3. Invert the vial. Holding the syringe plunger in a fully depressed position, pierce the vial stopper with the needle and withdraw the entire volume of solution into the syringe (the increased pressure in the vial will facilitate this). Keep the needle in the solution to avoid drawing in air. The solution withdrawn into the syringe may contain small carbon dioxide bubbles.

Important incompatibilities
Ceftazidime is less stable in sodium bicarbonate solutions than in other intravenous fluids. Sodium bicarbonate should not be used as a solvent.
Ceftazidime should not be mixed with aminoglycosides in the same infusion set or syringe.
Precipitation has been reported when vancomycin was added to a ceftazidime solution. It is recommended to flush the intravenous infusion sets and cannulae between administering the two antibiotics.

Storage after dissolution

Shelf life of the prepared solution
The chemical and physical stability of the prepared solution has been demonstrated for 6 hours at 25°C and for 12 hours at 2-8°C. After mixing with lidocaine: use immediately (within 2 hours). From a microbiological point of view, the prepared solution should be used immediately.